PriceTargets.com logo

Schrödinger - SDGR Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $32.90
  • Forecasted Upside: 54.03%
  • Number of Analysts: 11
  • Breakdown:
  • 0 Sell Ratings
  • 3 Hold Ratings
  • 7 Buy Ratings
  • 1 Strong Buy Ratings
$21.36 As of 12/17/2024 01:00 AM ET
▼ -0.28 (-1.29%)

This chart shows the closing price for SDGR by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Schrödinger Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for SDGR and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for SDGR

Analyst Price Target is $32.90
▲ +54.03% Upside Potential
This price target is based on 11 analysts offering 12 month price targets for Schrödinger in the last 3 months. The average price target is $32.90, with a high forecast of $50.00 and a low forecast of $25.00. The average price target represents a 54.03% upside from the last price of $21.36.

This chart shows the closing price for SDGR for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 11 investment analysts is to moderate buy stock in Schrödinger. This Moderate Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
6/27/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
9/25/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
12/24/2023
  • 0 strong buy ratings
  • 6 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
3/23/2024
  • 0 strong buy ratings
  • 6 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
6/21/2024
  • 1 strong buy ratings
  • 6 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
9/19/2024
  • 1 strong buy ratings
  • 7 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
11/18/2024
  • 1 strong buy ratings
  • 7 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
12/18/2024

Latest Recommendations

  • 1 strong buy ratings
  • 7 buy ratings
  • 3 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
11/13/2024BMO Capital MarketsBoost TargetOutperform ➝ Outperform$25.00 ➝ $28.00
10/17/2024BMO Capital MarketsLower TargetOutperform ➝ Outperform$30.00 ➝ $25.00
8/21/2024Morgan StanleyLower TargetEqual Weight ➝ Equal Weight$43.00 ➝ $30.00
7/11/2024KeyCorpLower TargetOverweight ➝ Overweight$30.00 ➝ $25.00
7/2/2024Leerink PartnrsUpgradeStrong-Buy
7/2/2024Leerink PartnersInitiated CoverageOutperform$29.00
5/2/2024CitigroupLower TargetBuy ➝ Buy$39.00 ➝ $37.00
5/2/2024Craig HallumLower TargetBuy ➝ Buy$35.00 ➝ $30.00
3/1/2024The Goldman Sachs GroupLower TargetNeutral ➝ Neutral$29.00 ➝ $26.00
2/29/2024KeyCorpLower TargetOverweight ➝ Overweight$38.00 ➝ $33.00
2/29/2024CitigroupLower TargetBuy ➝ Buy$47.00 ➝ $39.00
2/29/2024Bank of AmericaLower TargetNeutral ➝ Neutral$38.00 ➝ $32.00
2/29/2024Piper SandlerLower TargetOverweight ➝ Overweight$60.00 ➝ $50.00
1/26/2024TD CowenInitiated CoverageOutperform$42.00
1/19/2024Craig HallumLower TargetBuy ➝ Buy$40.00 ➝ $35.00
12/5/2023KeyCorpInitiated CoverageOverweight$38.00
11/13/2023Morgan StanleyLower TargetEqual Weight ➝ Equal Weight$52.00 ➝ $51.00
8/4/2023Morgan StanleyReiterated RatingEqual Weight ➝ Equal Weight$52.00
8/3/2023BMO Capital MarketsLower TargetOutperform ➝ Outperform$78.00 ➝ $67.00
6/29/2023Morgan StanleyBoost Target$38.00 ➝ $52.00
6/15/2023Jefferies Financial GroupBoost Target$40.00 ➝ $60.00
5/8/2023CitigroupLower Target$52.00 ➝ $50.00
5/5/2023Piper SandlerInitiated CoverageOverweight$60.00
3/10/2023Morgan StanleyBoost TargetEqual Weight$38.00 ➝ $39.00
3/1/2023BMO Capital MarketsLower TargetOutperform$83.00 ➝ $78.00
1/31/2023CitigroupBoost TargetBuy$48.00 ➝ $51.00
1/19/2023Piper SandlerBoost TargetOverweight$86.00 ➝ $87.00
12/19/2022The Goldman Sachs GroupInitiated CoverageNeutral$23.00
11/4/2022BMO Capital MarketsLower TargetOutperform$88.00 ➝ $83.00
11/4/2022Morgan StanleyLower TargetEqual Weight$39.00 ➝ $38.00
11/4/2022CitigroupLower Target$55.00 ➝ $48.00
9/9/2022Morgan StanleyBoost TargetEqual Weight$33.00 ➝ $39.00
8/24/2022Morgan StanleyLower TargetEqual Weight$34.00 ➝ $33.00
7/26/2022Piper SandlerBoost TargetOverweight$84.00 ➝ $86.00
2/28/2022CitigroupInitiated CoverageBuy$55.00
2/25/2022Piper SandlerLower Target$87.00 ➝ $84.00
11/19/2021Morgan StanleyDowngradeOverweight ➝ Equal Weight$82.00 ➝ $49.00
11/18/2021Piper SandlerInitiated CoverageOverweight$87.00
11/11/2021Craig HallumLower TargetBuy$85.00 ➝ $80.00
11/11/2021Bank of AmericaDowngradeBuy ➝ Neutral$80.00 ➝ $52.00
10/13/2021Berenberg BankInitiated CoverageBuy$91.00
9/1/2021Morgan StanleyUpgradeEqual Weight ➝ Overweight$82.00
5/25/2021Craig HallumInitiated CoverageBuy$85.00
5/12/2021Morgan StanleyLower TargetEqual Weight$89.00 ➝ $83.00
3/24/2021BMO Capital MarketsLower TargetOutperform$110.00 ➝ $104.00
1/25/2021BMO Capital MarketsBoost TargetOutperform$97.00 ➝ $117.00
11/23/2020Bank of AmericaUpgradeNeutral ➝ Buy$74.00
11/13/2020Morgan StanleyLower TargetEqual Weight$90.00 ➝ $89.00
10/13/2020Morgan StanleyLower TargetEqual Weight$93.00 ➝ $90.00
10/12/2020Jefferies Financial GroupUpgradeHold ➝ Buy$70.00 ➝ $75.00
7/15/2020Morgan StanleyBoost TargetEqual Weight$52.00 ➝ $93.00
6/2/2020BMO Capital MarketsBoost TargetPositive ➝ Outperform$67.00 ➝ $85.00
5/14/2020BMO Capital MarketsBoost TargetOutperform$65.00 ➝ $67.00
5/14/2020Morgan StanleyBoost TargetEqual Weight$43.00 ➝ $52.00
3/2/2020Jefferies Financial GroupInitiated CoverageHold$42.00
3/2/2020Morgan StanleyInitiated CoverageEqual Weight$43.00
3/2/2020BMO Capital MarketsInitiated CoverageOutperform$65.00
(Data available from 12/18/2019 forward)

News Sentiment Rating

1.12 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 4 very positive mentions
  • 11 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
5/22/2024
  • 7 very positive mentions
  • 5 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
6/21/2024
  • 5 very positive mentions
  • 2 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
7/21/2024
  • 10 very positive mentions
  • 10 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
8/20/2024
  • 6 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/19/2024
  • 6 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
10/19/2024
  • 7 very positive mentions
  • 15 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/18/2024
  • 9 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/18/2024

Current Sentiment

  • 9 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Schrödinger logo
Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on licensing its software to transform molecular discovery for life sciences and materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. The company serves biopharmaceutical and industrial companies, academic institutions, and government laboratories worldwide. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.
Read More

Today's Range

Now: $21.36
Low: $21.12
High: $21.85

50 Day Range

MA: $19.69
Low: $17.22
High: $22.57

52 Week Range

Now: $21.36
Low: $16.67
High: $38.00

Volume

700,133 shs

Average Volume

749,038 shs

Market Capitalization

$1.56 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.56

Frequently Asked Questions

What sell-side analysts currently cover shares of Schrödinger?

The following Wall Street analysts have issued research reports on Schrödinger in the last year: Bank of America Co., BMO Capital Markets, Citigroup Inc., Craig Hallum, KeyCorp, Leerink Partners, Leerink Partnrs, Morgan Stanley, Piper Sandler, TD Cowen, and The Goldman Sachs Group, Inc..
View the latest analyst ratings for SDGR.

What is the current price target for Schrödinger?

0 Wall Street analysts have set twelve-month price targets for Schrödinger in the last year. Their average twelve-month price target is $32.90, suggesting a possible upside of 54.0%. Piper Sandler has the highest price target set, predicting SDGR will reach $50.00 in the next twelve months. KeyCorp has the lowest price target set, forecasting a price of $25.00 for Schrödinger in the next year.
View the latest price targets for SDGR.

What is the current consensus analyst rating for Schrödinger?

Schrödinger currently has 3 hold ratings, 7 buy ratings and 1 strong buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for SDGR.

What other companies compete with Schrödinger?

Other companies that are similar to Schrödinger include Legend Biotech, Nuvalent, Ionis Pharmaceuticals, Blueprint Medicines and Elanco Animal Health. Learn More about companies similar to Schrödinger.

How do I contact Schrödinger's investor relations team?

Schrödinger's physical mailing address is 120 WEST 45TH STREET 17TH FLOOR, NEW YORK NY, 10036. The company's listed phone number is 212-295-5800 and its investor relations email address is [email protected]. The official website for Schrödinger is www.schrodinger.com. Learn More about contacing Schrödinger investor relations.